Distinct ERG rearrangement prevalence in prostate cancer: Higher frequency in young age and in low PSA prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 132-138

  Schaefer, G ^a,b   Mosquera, J M ^c   Ramoner, R ^a,d   Park, K ^b   Romanel, A ^e   Steiner, E ^a   Horninger, W ^a   Bektic, J ^a   Ladurner Rennau, M ^a   Rubin, M A ^c   Demichelis, F ^c,e   Klocker, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d University of Applied Sciences Tyrol   (Austria)

^e UNIVERSITY OF TRENTO   (Italy)

Author keywords

age; early onset prostate cancer; ERG frequency distribution; ERG overexpression; PSA screening

Indexed keywords

PROSTATE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ADULT; AGE; AGED; ARTICLE; BIOCHEMICAL CANCER RECURRENCE; BODY MASS; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; D'AMICO RISK SCORE; ERG GENE; FREE PROSTATE SPECIFIC ANTIGEN PERCENTAGE; GENE FREQUENCY; GENE OVEREXPRESSION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR GENE; TUMOR VOLUME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BODY MASS INDEX; EARLY DETECTION OF CANCER; GENE EXPRESSION; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84882448718     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.4     Document Type: Article

References (48)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 23: 1044-1052.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
5. Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23: 539-546.
6. Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-3385.
7. Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2- ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Sur Pathol 2007; 31: 882-888. (Pubitemid 47165141)
8. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with atypical glands suspicious for cancer. Am J Sur Pathol 2011; 35: 608-614.
9. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of erg rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012; 136: 935-946.
10. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341. (Pubitemid 44449140)
11. Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
12. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-237.
13. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010; 75: 762-767.
14. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012; 25: 471-479.
15. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarker Prev 2012; 21: 1497-1509.
16. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-263.
17. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-4599. (Pubitemid 47037039)
18. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS et al. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PloS One 2012; 7: e41668.
19. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PloS One 2011; 6: e21650.
20. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008; 101: 809-816. (Pubitemid 351347736)
21. Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G et al. Prostate- specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012; 57: 57-62.
22. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006; 164: 376-384. (Pubitemid 44297346)
23. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Sur Pathol 2005; 29: 1228-1242. (Pubitemid 41232997)
24. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, van Leenders GJLH et al. Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. Eur Urol 2010; 57: 821-829.
25. Lowrance WT, Scardino PT. Predictive models for newly diagnosed prostate cancer patients. Rev Urol 2009; 11: 117-126.
26. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75. (Pubitemid 351172158)
27. Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX et al. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci USA 2012; 109: 6686-6691.
28. Shaikhibrahim Z, Braun M, Nikolov P, Boehm D, Scheble V, Menon R et al. Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression. Hum Pathol 2012; 43: 1910-1916.
29. Svensson MA, LaFargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest 2011; 91: 404-412.
30. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71: 489-497.
31. Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 2010; 183: 2054-2061.
32. Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 4706-4711.
33. Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 2010; 23: 1492-1498.
34. Leinonen KA, Tolonen TT, Bracken H, Stenman U-H, Tammela TLJ, Saramaki OR et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-2851.
35. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: pathological features and ERG fusion status. J Urol 2011; 185: 489-494.
36. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M et al. Evaluation of the ETSrelated gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 2010; 16: 1572-1576.
37. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.
38. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG Gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2012; S0302-2838: 01345-0.
39. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Archiv 2011; 459: 441-447.
40. Tomlins SA, Aubin SMJ, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Science Tranl Med 2011; 3: 94ra72.
41. Elmlinger MW, Kuhnel W, Wormstall H, Doller PC. Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab 2005; 51: 625-632. (Pubitemid 41763079)
42. Gasi D, Trapman J. Androgen regulation of ETS gene fusion transcripts in prostate cancer. Methods Mol Biol 2011; 776: 335-348.
43. Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell 2010; 17: 415-416.
44. Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010; 12: 1031-1040.
45. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
46. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
47. Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S et al. Oncogenemediated alterations in chromatin conformation. Proc Natl Acad Sci USA 2012; 109: 9083-9088.
48. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-5888.